Authors: Sun-Taek Lim, Chang-Ryong Kim, Young-Duk Kim, South Korea


To evaluate the long-term functional and anatomical effectiveness of intravitreal bevacizumab treatment in eyes with macular edema due to branch retinal vein occlusion (BRVO).


In this retrospective interventional case series, 59 consecutive, previously untreated eyes with macular edema were treated with intravitreal bevacizumab (1.25 mg) injections (IVB) and followed for 9 months. The main outcome measures were visual acuity (VA) and central retinal thickness (CRT) by optical coherent tomography (OCT).

Effectiveness / Safety:

The mean corrected visual acuity (MCVA) before IVB was 0.32 and MCVA after IVB was 0.59 from baseline at 9 months. The mean central retinal thickness (MCRT) before IVB was 606 micrometers and the MCRT after IVB was 291 micrometers from baseline at 9 months. The mean number of re-injections was 1.9 during the 9 months of follow-up. Following IVB, VA increased in 51 eyes, decreased in 3 and remained the same in 5 eyes. Epiretinal membrane developed in 4 eyes and pars plana vitrectomy and removal of epiretinal membrane was performed in 2 eyes. Mild anterior uveitis occurred in 3 eyes. Endophthalmitis did not occur in any patient.

Take home message:

Intravitreal bevacizumab injection is a safe and effective treatment in patients with macular edema secondary to BRVO. But the main limitation is a high recurrence rate, so re-injections are necessary to maintain this effect.